**Symposium 171**

**Marriott Ballroom Salon 2, Sunday, 17 November, 10.15 am – 12.00 pm**

**Drug discovery as a tool for target identification**

Co-chairs: Paul Willis, MMV, Switzerland; Dyann Wirth, Harvard School of Public Health, USA

Speakers:

Dyann Wirth, Harvard School of Public Health, USA
R. Kiplin Guy, St. Jude Children's Research Hospital, USA
Francisco Javier Gamo-Benito, GlaxoSmithKline, Spain
Leslie Street, University of Cape Town, South Africa

**Poster presentations, Exhibit Hall B/C**

**Thursday, 14 November, 12.00 pm – 1.45 pm**

**Poster Session A**

LB-2126 Field performance of BinaxNOW® G6PD point of care diagnostics in *P. vivax* infected subjects before treatment with 8-aminoquinolines

Justin Green, GlaxoSmithKline, UK

**Friday, 15 November, 12.00 pm – 1.45 pm**

**Poster Session B**

645 Drug interaction evaluation of pyronaridine/artesunate and metoprolol and re-dosing evaluation of pyronaridine/artesunate in healthy volunteers

Carrie Morris, University of Iowa, USA

648 Benzoxaborole antimalarial agents: structure–activity relationship (SAR) of 6-substituted-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles

Yong-Kang Zhang, Anacor Pharmaceuticals, Inc., USA

652 Treatment of severe malaria – an operational comparison between quinine and artesunate for the treatment of severe malaria in seven health facilities in the Democratic Republic of the Congo – "MATIAS"

Christian Burri, Swiss Tropical and Public Health Institute, Switzerland

816 Transmission blocking properties of antimalarials

Koen Dechering, TropIQ Health Sciences, Netherlands

**Saturday, 16 November, 12.00 pm – 1.45 pm**

**Poster Session C**

1273 Characterization of the bc1 Qi Site as a novel antimalarial target

Allison Stickles, Oregon Health & Science University, USA

*Medicines for Malaria Venture*’s vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. [www.mmv.org](http://www.mmv.org) | [info@mmv.org](mailto:info@mmv.org)
**Symposium 100**

Marriott Ballroom Salon, Friday, 15 November, 4.00 pm – 5.45 pm

Scaling-up of effective treatment for severe malaria in health facilities and communities: challenges and market-based approaches

Co-chairs: Brenda Waning, UNITAID, Switzerland; George Jagoe, MMV, Switzerland

Speakers:
- Peter Kremsner, Eberhard Karls Universität, Germany
- Pierre Hugo, MMV, Switzerland
- Olugbenga Mokuolu, University of Ilorin, Nigeria
- James Tibenderana, Malaria Consortium, Uganda

Additional panelist: Martin De Smet, Médecins Sans Frontières, Belgium

**Symposium 105**

Delaware, Friday, 15 November, 4.00 pm – 5.45 pm

Clinical Group II and annual business meeting (American Committee on Clinical Tropical Medicine and Travelers’ Health)

Chair: M. Patricia Joyce, CDC, USA

Speakers:
- David Shlim, Jackson Hole Travel and Tropical Medicine, USA
- Paul Arguin, CDC, USA
- Timothy Wells, MMV, Switzerland
- M. Patricia Joyce, CDC, USA

**Late Breakers in Malaria Session**

Marriott Ballroom Salon 3, Friday, 15 November, 12.15 pm – 1.30 pm

175 Safety and efficacy of primaquine against relapse in Indonesian soldiers when combined with Eurartesim®, Pyramax®, or following artesunate treatment of acute vivax malaria: an interim analysis

Co-chairs: Carol Sibley, University of Washington, USA; Bagus Tjahjono, Indonesian Army Health Directorate, Indonesia

Speaker: Bagus Tjahjono

**Scientific session 17**

Maryland AB, Thursday, 14 November, 10.15 am – 12.30 pm

**Malaria: chemotherapy and drug development**

Co-chairs: Michael Edstein, Australian Army Malaria Institute, Australia; Allison Stickles, Oregon Health and Science University, USA

42A Dose-ranging efficacy results from the tafenoquine ‘DETECTIVE’ trial: a randomized, double-blind, multi-centre, parallel-group study for the radical cure of subjects with Plasmodium vivax malaria
   Marcus Lacera, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Brazil

42B A clinical summary of investigations to determine the haemolytic potential of tafenoquine in G6PD deficient subjects
   Justin Green, GlaxoSmithKline, UK

48 A dose-ranging study in the human induced blood-stage malaria model to define the anti-parasitic activity and pharmacokinetic–pharmacodynamic relationship of the synthetic peroxide antimalarial OZ439
   James McCarthy, QIMR Berghofer Medical Research Institute, Australia

**Symposium 88**

Marriott Ballroom Salon 1, Friday, 15 November, 1.45 pm – 3.30 pm

Building clinical trial capacities in Africa through north-south networking and public–private partnerships: example of the West African network for clinical trials of antimalarial drugs (WANECAM)

Co-chairs: Abdoulaye Djimde, University of Science, Techniques and Technologies of Bamako, Mali; Anders Bjorkman, Karolinska University Hospital, Sweden

Speakers:
- Abdoul Beavogui, Centre de Formation et de Recherche en Santé Rurale de Mafèrinyah, Guinea
- Ghiorghis Belai, Family Health International, Kenya
- Sodiomon Sirima, National Center for Research and Training on Malaria, Burkina Faso
- Abdoulaye Djimde